CH681304A5 - - Google Patents
Download PDFInfo
- Publication number
- CH681304A5 CH681304A5 CH1624/90A CH162490A CH681304A5 CH 681304 A5 CH681304 A5 CH 681304A5 CH 1624/90 A CH1624/90 A CH 1624/90A CH 162490 A CH162490 A CH 162490A CH 681304 A5 CH681304 A5 CH 681304A5
- Authority
- CH
- Switzerland
- Prior art keywords
- nedocromil
- pharmaceutical composition
- particles
- sodium
- particle size
- Prior art date
Links
- 239000002245 particle Substances 0.000 claims description 54
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 claims description 24
- 229960002259 nedocromil sodium Drugs 0.000 claims description 24
- 229960004398 nedocromil Drugs 0.000 claims description 16
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 238000001228 spectrum Methods 0.000 claims description 9
- 239000008188 pellet Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- JQEKDNLKIVGXAU-UHFFFAOYSA-L nedocromil sodium Chemical compound [Na+].[Na+].CCN1C(C([O-])=O)=CC(=O)C2=C1C(CCC)=C1OC(C([O-])=O)=CC(=O)C1=C2 JQEKDNLKIVGXAU-UHFFFAOYSA-L 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- WTLBZVNBAKMVDP-UHFFFAOYSA-N tris(2-butoxyethyl) phosphate Chemical compound CCCCOCCOP(=O)(OCCOCCCC)OCCOCCCC WTLBZVNBAKMVDP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898911259A GB8911259D0 (en) | 1989-05-17 | 1989-05-17 | Inhalation medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH681304A5 true CH681304A5 (instruction) | 1993-02-26 |
Family
ID=10656851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1624/90A CH681304A5 (instruction) | 1989-05-17 | 1990-05-14 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0398631A1 (instruction) |
| JP (1) | JPH035483A (instruction) |
| BE (1) | BE1003311A5 (instruction) |
| CA (1) | CA2016926A1 (instruction) |
| CH (1) | CH681304A5 (instruction) |
| FR (1) | FR2647115B1 (instruction) |
| GB (2) | GB8911259D0 (instruction) |
| GR (1) | GR1000809B (instruction) |
| IE (1) | IE66154B1 (instruction) |
| LU (1) | LU87738A1 (instruction) |
| PT (1) | PT94053A (instruction) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9323132D0 (en) * | 1993-11-10 | 1994-01-05 | Fisons Plc | New pharmaceutical use |
| GB9820746D0 (en) † | 1998-09-23 | 1998-11-18 | Pharmax Limited | Micronised pharmaceutical compositions |
| GB9925934D0 (en) * | 1999-11-03 | 1999-12-29 | Glaxo Group Ltd | Novel apparatus and process |
| GB9928311D0 (en) * | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
| BRPI0502339A (pt) * | 2005-06-16 | 2007-02-06 | Maqsoy Tecnologia Em Alimentos | equipamento e processo para produção de farinha de soja |
| TR200907914A2 (tr) * | 2009-10-20 | 2011-05-23 | B�Lg�� Mahmut | Kortlkosteroid içeren kuru toz formunda farmasötik bileşim. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1520247A (en) * | 1974-08-10 | 1978-08-02 | Fisons Ltd | Pelletised medicament formulations |
| GB2105189B (en) * | 1981-07-24 | 1985-03-20 | Fisons Plc | Inhalation drugs |
| EP0162556B1 (en) * | 1984-04-13 | 1991-11-06 | FISONS plc | Novels forms and formulations of nedocromil sodium |
| GB2196254B (en) * | 1984-04-13 | 1988-08-10 | Fisons Plc | Formulations of nedocromil sodium |
| GB2187953B (en) * | 1986-03-15 | 1989-11-15 | Fisons Plc | Pharmaceutical formulation |
| EP0294914A3 (en) * | 1987-03-17 | 1990-10-10 | FISONS plc | Nedocromil for the treatment of dermatological disorders |
| GB8712251D0 (en) * | 1987-05-23 | 1987-07-01 | Fisons Plc | Formulation |
| GB8820267D0 (en) * | 1988-08-26 | 1988-09-28 | Fisons Plc | Pharmaceutical formulation |
| GB8820398D0 (en) * | 1988-08-27 | 1988-09-28 | Fisons Plc | Pharmaceutical formulation |
-
1989
- 1989-05-17 GB GB898911259A patent/GB8911259D0/en active Pending
-
1990
- 1990-05-14 GR GR900100364A patent/GR1000809B/el unknown
- 1990-05-14 CH CH1624/90A patent/CH681304A5/fr not_active IP Right Cessation
- 1990-05-15 GB GB9010820A patent/GB2232891B/en not_active Expired - Fee Related
- 1990-05-15 EP EP90305202A patent/EP0398631A1/en not_active Withdrawn
- 1990-05-16 PT PT94053A patent/PT94053A/pt not_active Application Discontinuation
- 1990-05-16 JP JP2124331A patent/JPH035483A/ja active Pending
- 1990-05-16 IE IE177090A patent/IE66154B1/en unknown
- 1990-05-16 CA CA002016926A patent/CA2016926A1/en not_active Abandoned
- 1990-05-16 BE BE9000512A patent/BE1003311A5/fr not_active IP Right Cessation
- 1990-05-16 FR FR909006135A patent/FR2647115B1/fr not_active Expired - Fee Related
- 1990-05-17 LU LU87738A patent/LU87738A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2016926A1 (en) | 1990-11-17 |
| GB8911259D0 (en) | 1989-07-05 |
| GB2232891A (en) | 1991-01-02 |
| GR1000809B (el) | 1993-01-25 |
| GB9010820D0 (en) | 1990-07-04 |
| LU87738A1 (fr) | 1991-12-16 |
| GB2232891B (en) | 1993-02-03 |
| EP0398631A1 (en) | 1990-11-22 |
| FR2647115B1 (fr) | 1994-09-09 |
| PT94053A (pt) | 1991-01-08 |
| IE901770L (en) | 1990-11-17 |
| IE66154B1 (en) | 1995-12-13 |
| JPH035483A (ja) | 1991-01-11 |
| GR900100364A (en) | 1991-10-10 |
| BE1003311A5 (fr) | 1992-02-25 |
| FR2647115A1 (fr) | 1990-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2510405A1 (fr) | Composition pharmaceutique a inhaler | |
| JPH09507049A (ja) | ドライパウダー吸入器に用いられるキャリア粒子の改善 | |
| RU2170082C2 (ru) | Способ обработки лекарственного средства, устройство для формирования лекарственного средства и лекарственное средство | |
| CN103917223B (zh) | 供吸入的药用组合物 | |
| EP2535114A1 (en) | Fine powder manufacturing method and fine powder manufactured using same | |
| FR2759908A1 (fr) | Nouvelle composition pour inhalation | |
| OA12522A (en) | Novel tiotropium-containing inhalation powder. | |
| BR9612950B1 (pt) | pó para uso em inaladores de pó seco. | |
| CN106687112A (zh) | 醋酸阿比特龙制剂和使用方法 | |
| Desavathu et al. | Design, development and characterization of valsartan microsponges by quasi emulsion technique and the impact of stirring rate on microsponge formation | |
| ES2215628T5 (es) | Aglomerados obtenidos por cristalización. | |
| FR2759907A1 (fr) | Nouvelle composition pour inhalation | |
| CH681304A5 (instruction) | ||
| Pachuau et al. | Formulation and evaluation of matrix microspheres for simultaneous delivery of salbutamol sulphate and theophylline | |
| Heng et al. | Role of surfactant on drug release from tablets | |
| CA2613977C (fr) | Procede de production d'une poudre contenant des particules cristallines de xylitol avec un autre polyol | |
| CH621060A5 (en) | Granular medication | |
| FR2759905A1 (fr) | Nouvelle composition pour inhalation | |
| CN104510758B (zh) | 一种水牛角浓缩粉及浓缩水牛角颗粒的制备方法 | |
| EP1824456A2 (fr) | Azodicarbonamide micronise, sa preparation et son utilisation | |
| Bakliwal et al. | FORMULATION AND EVALUATION OF NATEGLINIDE NANOSPONGES. | |
| AU2003226842B2 (en) | A method for treating carrier particles and its use | |
| CN114375229B (zh) | 分级分离用于药物组合物的颗粒的方法和设备 | |
| US5198221A (en) | Pharmaceutical composition | |
| GB2224628A (en) | Processes for selectively comminuting and purifying psyllium seed husk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |